Pubblicazioni

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide

2022 - MINERVA UROLOGY AND NEPHROLOGY

Sciarra, A.; Gentilucci, A.; Cattarino, S.; Salsiccia, S.; Mariotti, G.

Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics

2022 - MOLECULAR METABOLISM

Chianese, Ugo; Papulino, Chiara; Passaro, Eugenia; Evers, Tom Mj; Babaei, Mehrad; Toraldo, Antonella; De Marchi, Tommaso; NimÃ©us, Emma; Carafa, Vincenzo; Nicoletti, Maria Maddalena; Del Gaudio, Nunzio; Iaccarino, Nunzia; Randazzo, Antonio; Rotili, Dante; Mai, Antonello; Cappabianca, Salvatore; Mashaghi, Alireza; Ciardiello, Fortunato; Altucci, Lucia; Benedetti, Rosaria

Prognostic and theranostic applications of positron emission tomography for a personalized approach to metastatic castrationâresistant prostate cancer

2021 - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Filippi, L.; Frantellizzi, V.; Chiaravalloti, A.; Pontico, M.; De Feo, M. S.; Corica, F.; Montebello, M.; Schillaci, O.; De Vincentis, G.; Bagni, O.

Potential prognostic value of miR-132 and miR-212 expression in mCRPC patients

2021 - ARCHIVIO ITALIANO DI UROLOGIA ANDROLOGIA

Pontico, M.; Frantellizzi, V.; Cindolo, L.; de Vincentis, G.

Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test

2019 - JAMA ONCOLOGY

Nicolazzo, C.; Gradilone, A.; Gazzaniga, P.

Molecular basis of drug resistance and insights for new treatment approaches in mCRPC

2018 - ANTICANCER RESEARCH

Giacinti, Silvana; Poti, Giulia; Roberto, Michela; Macrini, Serena; Bassanelli, Maria; Di Pietro, Francesca; Aschelter, Anna Maria; Ceribelli, Anna; Ruggeri, Enzo Maria; Marchetti, Paolo

Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study

2015 - EUROPEAN UROLOGY

Caffo, Orazio; De Giorgi, Ugo; Fratino, Lucia; Alesini, Daniele; Zagonel, Vittorina; Facchini, Gaetano; Gasparro, Donatello; Ortega, Cinzia; Tucci, Marcello; Verderame, Francesco; Campadelli, Enrico; Lo Re, Giovanni; Procopio, Giuseppe; Sabbatini, Roberto; Donini, Maddalena; Morelli, Franco; Sartori, Donata; Zucali, Paolo; Carrozza, Francesco; D'Angelo, Alessandro; Vicario, Giovanni; Massari, Francesco; Santini, Daniele; Sava, Teodoro; Messina, Caterina; Fornarini, Giuseppe; La Torre, Leonardo; Ricotta, Riccardo; Aieta, Michele; Mucciarini, Claudia; Zustovich, Fable; Macrini, Sveva; Burgio, Salvatore Luca; Santarossa, Sandra; D'Aniello, Carmine; Basso, Umberto; Tarasconi, Sara; Cortesi, Enrico; Buttigliero, Consuelo; Ruatta, Fiorella; Veccia, Antonello; Conteduca, Vincenza; Maines, Francesca; Galligioni, Enzo

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4). A double-blind, multicentre, phase 3, randomised, placebo-controlled trial

2015 - THE LANCET ONCOLOGY

Saad, Fred; Fizazi, Karim; Jinga, Viorel; Efstathiou, Eleni; Fong, Peter C; Hart, Lowell L; Jones, Robert; Mcdermott, Raymond; Wirth, Manfred; Suzuki, Kazuhiro; Maclean, David B; Wang, Ling; Akaza, Hideyuki; Nelson, Joel; Scher, Howard I; Dreicer, Robert; Webb, Iain J; de Wit, Ronald; Collaborators, ; Tubaro, Andrea